TransCode's TTX-MC138 Enters Phase 2a Trial in Quantum Leap PRE-I-SPY Platform

TransCode Therapeutics and Quantum Leap Healthcare Collaborative have announced a collaboration to evaluate TTX-MC138 in a Phase 2a trial. TTX-MC138, a therapeutic candidate designed to inhibit microRNA-10b, a biomarker linked to metastatic cancers, achieved its primary safety endpoint and established a recommended Phase 2 dose in its Phase 1a trial. The Phase 2a study will enroll up to 45 patients with colorectal cancer who have completed standard therapy but remain ctDNA-positive, indicating minimal residual disease. The study aims to evaluate the biological and clinical activity of TTX-MC138 in the MRD setting.